Skip to main content

News

GUIDELINES
08/30/2024
Whereas prior guidelines generally recommended patients be treated to a BP
Whereas prior guidelines generally recommended patients be treated to a BP
Whereas prior guidelines...
08/30/2024
Cath Lab Digest
Sleep and CVD
08/29/2024
The UK Biobank study of more than 90,000 individuals showed that those who had the most catch-up sleep on weekends had a 20% lower risk of developing heart disease than those with the least.
The UK Biobank study of more than 90,000 individuals showed that those who had the most catch-up sleep on weekends had a 20% lower risk of developing heart disease than those with the least.
The UK Biobank study of more...
08/29/2024
Cath Lab Digest
Press Release
08/29/2024
iRhythm Technologies Press Release Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization...
iRhythm Technologies Press Release Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization...
iRhythm Technologies Press...
08/29/2024
EP Lab Digest
ESC2024
08/28/2024
Professor Adam Timmis pointed to new data suggesting that treatment factors may contribute to inequalities in CVD mortality, with middle-income countries substantially under-resourced in terms of specialist staffing, and diagnostic and...
Professor Adam Timmis pointed to new data suggesting that treatment factors may contribute to inequalities in CVD mortality, with middle-income countries substantially under-resourced in terms of specialist staffing, and diagnostic and...
Professor Adam Timmis pointed to...
08/28/2024
Cath Lab Digest
Press Release
08/27/2024
AtriCure, Inc., Press Release August 27, 2024 08:00 AM Eastern Daylight Time--MASON, Ohio--AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and...
AtriCure, Inc., Press Release August 27, 2024 08:00 AM Eastern Daylight Time--MASON, Ohio--AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and...
AtriCure, Inc., Press...
08/27/2024
EP Lab Digest
Press Release
08/27/2024
OMRON Healthcare Press Release KYOTO, Japan, Aug. 27, 2024 -- OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces attendance and sponsorship of the annual congress of the European Society of...
OMRON Healthcare Press Release KYOTO, Japan, Aug. 27, 2024 -- OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces attendance and sponsorship of the annual congress of the European Society of...
OMRON Healthcare Press...
08/27/2024
EP Lab Digest
Press Release
08/27/2024
PaceMate Press Release SARASOTA, Fla. -- PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from...
PaceMate Press Release SARASOTA, Fla. -- PaceMate®, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from...
PaceMate Press...
08/27/2024
EP Lab Digest
Press Release
08/26/2024
Expanded indication based on an abundance of clinical evidence for AtriClip Devices
Expanded indication based on an abundance of clinical evidence for AtriClip Devices
Expanded indication based on an...
08/26/2024
EP Lab Digest
Press Release
08/26/2024
Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes
Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes
Risk Predication Tool, Developed...
08/26/2024
EP Lab Digest
Press Release
08/26/2024
New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
New analyses, including presentations on CAMZYOS® (mavacamten), ELIQUIS® (apixaban) and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
New analyses, including...
08/26/2024
EP Lab Digest